You just read:

Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

Jul 31, 2018, 08:00 ET